Immunovant, Inc. IMVT

Immunovant announced top-line results from a proof-of-concept study of IMVT-1402 for cutaneous lupus erythematosus (CLE). The randomized trial failed to meet the primary endpoint—the percent change in the CLE disease activity score after 12 weeks—although some efficacy signals emerged, including greater IgG reductions associated with better outcomes. IMVT-1402 was generally well tolerated, but Immunovant decided to discontinue the CLE program. The news sparked a stock drop of about 7.4%, though the company said its broader pipeline remains on track, with registrational studies for IMVT-1402 in Graves' disease and myasthenia gravis expected in 2027 and studies in CIDP and Sjögren's disease planned for 2028. Ceasing the CLE program is a meaningful setback, though other IMVT-1402 programs and registrational timelines remain intact.

Roivant reported top-line data from IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). In a randomized, double-blind, placebo-controlled trial with 57 adults, the primary endpoint—change in CLASI-A score after 12 weeks—was not met. Immunovant observed numerical trends favoring IMVT-1402 on several secondary endpoints and noted that greater IgG reductions from baseline aligned with better responses, but the company decided to stop CLE development. Immunovant will instead pursue IMVT-1402 in other autoimmune diseases. Ongoing indications include chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Graves' disease, myasthenia gravis, and Sjögren's disease. Roivant's pipeline also features Lisraya and mosliciguat, and the firm cited prior positive NEPTUNE results for brepocitinib in NIU. CEO Eric Venker thanked CLE participants and investigators. Discontinuing CLE development reduces near-term upside for IMVT-1402 but allows redirection to other autoimmune programs.

Immunovant's IMVT-1402 failed to meet its primary endpoint in a 57-patient cutaneous lupus erythematosus (CLE) study after 12 weeks, prompting the company to suspend CLE development due to a competitive landscape. While some positive signals emerged—greater IgG reductions correlated with better responses—the proof-of-concept did not reach the internal threshold. The setback leaves IMVT-1402 as the core program, but development continues in other autoimmune indications (Graves' disease, myasthenia gravis, CIDP, Sjögren's, and difficult-to-treat rheumatoid arthritis). Topline data for Graves' disease and MG are expected in 2027, with CIDP and Sjögren's data in 2028. Cash totaled $797.8 million as of June 30, down from $902.1 million, funding operations through a potential Graves' launch. Shares fell ~6%, with bearish sentiment on Stocktwits and shares near three-month lows. Stopping CLE after a failed trial represents a major strategic shift that could significantly affect near-term value and pipeline progression.

Roivant Sciences' Immunovant said it will discontinue development of IMVT-1402 (imeroprubart) for cutaneous lupus erythematosus after a randomized, double-blind trial failed to meet the primary endpoint, CLASI-A at Week 12, in 57 adults. Immunovant attributed the decision to clinical results and the competitive landscape, noting numerical trends favored the drug on several endpoints and that greater reductions in immunoglobulin G correlated with better responses. The company reported the drug's safety profile remained consistent with prior studies. Development for IMVT-1402 will continue in other autoimmune indications, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP, and Sjögren's disease, with timelines for other programmes on track. Cessation of a single indication narrows the pipeline but leaves other programs intact, limiting overall impact.

Immunovant shares fell about 6% after reporting that IMVT-1402 failed to meet its primary endpoint in a proof-of-concept trial for cutaneous lupus erythematosus. The randomized, double-blind, placebo-controlled study enrolled 57 adults over 12 weeks. The primary endpoint was the percent change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity score at Week 12. Immunovant said results did not meet its internal criteria for continuing development of IMVT-1402 (imeroprubart) for cutaneous lupus erythematosus and plans to discontinue the program for this indication. Although numerical trends favored IMVT-1402 on several endpoints and greater IgG reductions appeared linked to better responses, the company cited the overall outcome and competitive landscape in deciding not to pursue this indication. Safety and tolerability were consistent with prior trials. Other IMVT-1402 programs remain on track in Graves' disease, difficult-to-treat RA, myasthenia gravis, CIDP and Sjögren's disease. Discontinuation of IMVT-1402 for cutaneous lupus lowers near-term pipeline potential, while other programs remain on track.

Immunovant announced topline results from Period 1 of a randomized, double-blind, placebo-controlled trial of IMVT-1402 in cutaneous lupus erythematosus. The primary endpoint—percent change from baseline in CLASI-A at Week 12—was not met. Numerical trends favored IMVT-1402 and deeper IgG reductions correlated with better responses, but the study failed to meet the internal criteria to continue CLE development. Despite a favorable safety profile, Immunovant said it will discontinue CLE development and focus on IMVT-1402 in other autoimmune diseases (e.g., Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP, Sjogren's). All other clinical timelines remain on track. The trial enrolled 57 adults; Period 1 spanned 12 weeks. Stopping CLE development narrows IMVT-1402's potential and may dampen near-term value while other indications remain active.

Roivant Sciences said Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not meet its primary endpoint, the CLASI-A percent change at Week 12, in Period 1 of a 12-week randomized trial that enrolled 57 adults. While numerical trends favored IMVT-1402 and deeper IgG reductions tracked with better responses, Immunovant will stop CLE development and pivot to other IgG-mediated autoimmune diseases. The drug showed a favorable safety and tolerability profile consistent with prior studies. Immunovant maintains other clinical timelines, pursuing indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, and Sjögren's. CEO Eric Venker emphasized gratitude to participants; the press release includes standard forward-looking statements. CLE program termination represents a meaningful shift in pipeline risk and investor sentiment, though other indications remain in development.

Rosnilimab advances as a promising rheumatoid arthritis therapy, drawing physician attention toward the next wave of pipeline options in the space. Rosnilimab progress introduces moderate competitive pressure on IMVT's rheumatoid arthritis pipeline positioning.

Immunovant (IMVT) released its Q1 2027 earnings call transcript detailing financial results, operational updates, and strategic outlook. Quarterly earnings calls typically deliver financial metrics and guidance that produce moderate short-term market reactions.

Roivant Sciences Q1 earnings call covered financial results and strategic updates including progress on Immunovant (IMVT) programs and pipeline milestones. Earnings call details provide moderate updates on financials and pipeline but do not indicate major strategic shifts for Immunovant.

Immunovant, Inc. released its Q1 2027 earnings call summary covering quarterly financial results, pipeline updates and forward outlook. Quarterly earnings update provides financial metrics and guidance that may influence near-term sentiment without altering long-term trajectory.

Immunovant Q1 earnings call covered financial results, ongoing IMVT-1402 development for autoimmune indications, cash runway guidance, and upcoming clinical milestones. Quarterly earnings call supplies routine financial and pipeline updates that moderately influence near-term sentiment but rarely shift long-term company trajectory.

Immunovant posted a wider-than-expected Q1 loss while its pipeline continues to advance. Wider quarterly loss points to near-term financial pressure offset by pipeline progress that may influence future positioning.

Immunovant reports strong IMVT-1402 Phase 2 rheumatoid arthritis trial results, triggering valuation reassessment for the company. Positive Phase 2 trial data for IMVT-1402 signals major pipeline progress that can shift company trajectory and investor sentiment.

H.C. Wainwright raised its price target on Immunovant after positive rheumatoid arthritis trial data. Positive rheumatoid arthritis trial data triggered analyst price target increase, marking major clinical progress with direct effects on valuation and sentiment.

Immunovant shares rose 355%. One fund took a $169 million position in the stock last quarter. Large new institutional stake plus extreme share-price gain signal major investor interest likely to shift sentiment and valuation.

Immunovant shares surge 60% after a top healthcare fund adds another $11 million to its stake. Fund stake increase signals stronger institutional interest that may lift near-term sentiment and valuation.

Immunovant shares rose 17.9% after refocusing development on IMVT-1402 despite wider losses, prompting questions over whether the prior bull case remains intact. Refocus on IMVT-1402 constitutes a major strategic shift that can materially alter pipeline direction and investor sentiment.

Immunovant posted wider-than-expected Q4 loss yet shares surged 35% after strong study data. Strong study data drove 35% stock gain despite wider loss indicating major clinical progress ahead.

Immunovant shares reach 5-year high after strong results from arthritis treatment clinical trial. Successful arthritis trial results drive Immunovant to five-year stock peak and signal major growth prospects.

Immunovant explores a new arthritis drug that could elevate the company into a leading biotech position. New arthritis drug development targets a core therapeutic area and could materially shift Immunovant's competitive standing and investor outlook.

Immunovant shares surged with another biotech stock, positioning the company for a potential trading breakout amid heightened investor interest. Sharp price gains and breakout setup indicate strong momentum likely to boost near-term valuation and sentiment for Immunovant.

Immunovant shares surge 22% after positive trial data release, with earnings report becoming secondary. Positive trial results trigger 22% stock jump and signal major progress in drug development pipeline.

Immunovant shares rallied after positive trial results despite an earnings miss. Positive clinical trial outcomes for Immunovant signal major pipeline progress likely to reshape investor outlook and long-term valuation.

Immunovant’s autoimmune candidate shows blockbuster potential while Wave reports progress on RNA editing. Blockbuster potential for Immunovant’s lead autoimmune program can materially lift valuation and pipeline outlook.

Immunovant reported Q4 results during its earnings call, detailing financials, cash position, and updates on batoclimab and IMVT-1402 development programs targeting autoimmune indications with ongoing and planned clinical trials. Quarterly updates cover pipeline timelines and cash runway that can shift near-term sentiment but do not signal immediate major changes to long-term trajectory.

Roivant reported financial results for the fourth quarter and fiscal year ended March 31, 2026, and issued a business update relevant to its Immunovant subsidiary. Quarterly financial results and business updates can influence near-term sentiment and valuation but rarely alter long-term trajectory by themselves.

Immunovant (IMVT) stock declined 2.4% after batoclimab failed to meet endpoints in a late-stage study. Batoclimab's late-stage failure threatens Immunovant's lead pipeline candidate and investor confidence.

Brepocitinib advances to new clinical trials while Batoclimab encounters a setback, prompting questions on whether Roivant Sciences (ROIV) investors should take action, with implications for Immunovant (IMVT) due to its Batoclimab program. Batoclimab setback directly jeopardizes Immunovant's lead asset and pipeline trajectory.

Immunovant's batoclimab failed Phase 3 trial in thyroid eye disease (TED), prompting discontinuation, while parent Roivant expands brepocitinib into lichen planopilaris (LPP). Batoclimab Phase 3 flop halts Immunovant's key TED program, likely causing major stock decline and pipeline uncertainty.